SEKUNDARNI HIPERPARATIREOIDIZAM I KARDIO-RENALNI SINDROM TIP 4: ETIOPATOGENEZA, KLINIČKI ZNAČAJ I LEČENJE
Sažetak
Uvod. Kardio-renalni sindrom je patofiziološki poremećaj funkcije srca i bubrega, gde akutni ili hronični poremećaj funkcije jednog organa podstiče akutni ili hronični poremećaj funkcije drugog organa. U kardio-renalnom sindromu tip 4 (hronični reno-kardijalni sindrom) nedostatak vitamina D i sekundarni hiperparatireoidizam dovode do poremećaja funkcije srca i bubrega. Cilj. Rad je imao za cilj da analizira faktore rizika, patogenetske mehanizme razvoja sekundarnog hiperparatireoidizma, kliničke posledice i da ukaže na klinički značaj njegovog ranog otkrivanja i pravovremenog lečenja. Metod. Analizirani su stručni radovi i kliničke studije koje se bave etiopatogenezom, dijagnostikom i lečenjem sekundarnog hiperparatireoidizma. Rezultati. U hroničnoj bolesti bubrega (stadijum 2 i 3) uključuju se mehanizmi adaptacije, povećava se koncentracija FGF-23 i parathormona u serumu. Ovi hormoni povećavaju frakcionu ekskreciju fosfata na nivou bubrega, a parathormon oslobađa kalcijum iz koštanog tkiva i na taj način održavaju koncentraciju kalcijuma i fosfata u serumu u normalnom rasponu. Gubitak sposobnosti bubrega da stvara aktivni metablit vitamina D i izlučuje fosfat iz organizma značajno doprinosi razvoju i napredovanju kardio-renalnog sindroma tip 4. Glavne kliničke posledice sekundarnog hiperparatiroeidizma su koštana bolest ubrzanog prometa, vaskularne i valvularne kalcifikacije i razvoj bolesti srca. Savremeno lečenje uključuje primenu: vezača fosfata koji ne sadrže kalcijum, novih analoga vitamina D i primenu kalcimimetika. Zaključak. Rana dijagnostika i optimalna kontrola sekundarnog hiperparatireoidizma sprečavaju progresiju hronične bolesti bubrega, ravoj kardiovaskularnih bolesti, smanjuju stopu kardiovaskularnog morbiditeta i mortaliteta i popravljaju kvalitet života ovih bolesnika.
Reference
Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34(5): 957-62.
Ronco C, Haapio M, House AA, Anaveker N, Bellomo R. Cardiorenal Syndrome. J Am Coll Cardiol 2008; 52(19): 1527-39.
Ronco C, Chionh C-Y, Maapio M, Anavekar NS, House A, Bellomo R. The Cardiorenal Syndrome. Blood Purif 2009; 27(1): 114-26.
Ronco C, McCullough, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010; 31(6): 703-11.
Petrović D, Jagić N, Miloradović V, Nikolić A, Stojimirović B. Cardiorenal syndrome - definition, classification and basic principles of therapy. Ser J Exp Clin Res 2010; 11(2): 67-71.
McCullough P, Goel S, Bellovich K. Preventing and Managing Cardiorenal Syndromes. US Nephrology 2010; 5(2): 50-4.
McCullough PA, Ahmed A. Cardiorenal syndromes. World J Cardiol 2011; 3(1): 1-9.
Petrović D, Milovanović D, Nikolić A, Miloradović V, A, Petrović M, Đurđević P, Poskurica M. Kardio-renalni sindrom tip 2: etiopatogeneza, dijagnostika i lečenje. Medicinski Časopis 2012; 46: (1): 30-4.
Moorthi RN, Moe SM. CKD-Mineral and Bone Disorder: Core Curriculum 2011. Am J Kidney Dis 2011; 58(6): 1022-36.
Cunningham J, Locatelli F, Rodriguez M. Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options. Clin J Am Soc Nephrol 2011; 6(4): 913-21.
Wolf M. Forging Forward with 10 Burning Questions on FGF23 in Kidney Disease. J Am Soc Nephrol 2010; 21(9): 1427-35.
Lee JH, O,Keefr JH, Bell D, Hensurd DD, Holick MF. Vitamin D Deficiency. J Am Coll Cardiol 2008; 52(24): 1949-56.
Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J. The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010; doi: 10.1093/ndt/gfq313.
Pateinakis P, Papagianni A. Cardiorenal Syndrome type IV-Cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management. Int J Nephrol 2011; ID: 938651.
Stojimirović B, Petrović D. Klinički značaj kontrole faktora rizika u sprečavanju progresije hronične slabosti bubrega. Vojnosanit Pregl 2006; 63(6): 585-91.
Gupta D, Brietzke S, Hayden MR, Kurukulasuriya LR, Sowers JR. Phosphate Metabolism in Cardiorenal Metabolic Disease. Cardiorenal Med 2011; 1(4): 261-70.
Ronco C, Cozzolino M. Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. Heart Fail Rev 2011; DOI: 10.1007/s10741-011-9232-8.
Coladonato JA. Control of Hyperphosphatemia among Patients with ESRD. J Am Soc Nephrol 2005; 16(11 Suppl 2): 107-14.
Petchey WG, Johnson DW, Isbel NM. Shining D, light on chronic kidney disease: Mechanisms that may underpin the cardiovascular benefit of vitamin D. Nephrology 2011; 16(4): 351-67.
Artaza JN, Mehrotra R, Norris KC. Vitamin D and the Cardiovascular System. Clin J AM Soc Nephrol 2009; 4(9): 1515-22.
Witham MD. Vitamin D in Chronic Heart Failure. Curr Heart Fail Rep 2011; 8(2): 123-30. (21)
Johnson RC, Leopolod JA, Loscalzo J. Vascular Calcification: Pathobiology Mechanisms and Clinical Implications. Circ Res 2006; 99(10): 1044-59.
Mizobuchi M, Towler D, Slatopolsky E. Vascular Calcification: The Killer of Patients with Chronic Kidney Disease. J Am Soc Nephrol 2009; 20(7): 1453-64.
Ketteler M, Rothe H, Krüger T, Biggar PH, Schlieper G. Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol 2011; 7(9): 509-16.
Shroff RC, Shanahan CM. Pathogenesis of vascular calcification: experimental studies. In: The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Olgaard K, Salusky IB, Silver J, eds. New York: Oxford University Press 2010: 283-301.
Eddington H, Klara PA. The association of chronic kidney disease-mineral bone disorder and cardiovascular risk. J Ren Car 2010; 36(Suppl 1): 61-7.
Schiffrin EL, Lipman ML, Mann JFE. Chronic Kidney Disease: Effects on the Cardiovascular System. Circulation 2007; 116(1): 85-97.
National Kidney Foundation. Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003; 42(4 Suppl 3): 1-201.
KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113): 1-130.
Raggi P, London GM. Non-invasive assessment of vascular calcification and arterial stiffness. In: The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Olgaard K, Salusky IB, Silver J, eds. New York: Oxford University Press 2010: 217-34.
Jiwakanon S, Chiu Y-W, Mehrotra R. Should Vascular Calcification Be Routinely Measured in Dialysis Patients? Semin Dial 2010; 23(3): 263-6.
Block GA. Screening Dialysis Patients for Vascular Calcification. Semin Dial 2010; 23(3): 271-6.
Rubin MF, Rosas SE, Chirinos JA, Townsend RR. Surrogate Markers of Cardiovascular Disease in CKD: Whats Under the Hood?. Am J Kidney Dis 2011; 57(3): 488-97.
Karohl C, Gascon LDM, Raggi P. Noninvasive imaging for assessment of calcification in chronic kidney disease. Nat Rev Nephrol 2011; 7(10): 567-77.
Petrović D, Obrenović R, Stojimirović B. Risk Factors for Aortic Valve Calcification in Patients on Regular Hemodialysis. Int J Artif Organs 2009; 32(3): 173-9.
Petrović D, Stojimirović B. Sekundarni hiperparatireoidizam - faktor rizika za razvoj kardiovaskularnih komplikacija kod bolesnika na hemodijalizi. Med Pregl 2010; LXIII(9-10): 674-80.
Petrović D, Jagić N, Miloradović V, Nikolić A, Stojimirović B. Diagnostics and therapy of left ventricular hypertrophy in hemodialysis patients. Ser J Exp Clin Res 2011; 12(1): 37-40.
Garimella PS, Harl PD, Ohare A, DeLoach S, Herzog CA, Hirsch AT. Peripheral Artery Disease and CKD: A Focus Peripheral Disease as a Critical Component of CKD Care. Am J Kidney Dis 2012; 60(4): 641-54.
Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 2010; 96(11): 817-23.
Tomasello S. Secondary Hyperparathyroidism and Chronic Kidney Disease. Diabetes Spectrum 2008; 21(1): 19-25.
Coladonato JA. Control of Hyperphosphatemia among Patients with ESRD. J Am Soc Nephrol 2005; 16(11 Suppl 2): 107-14.
Hutchison AJ, Smith CP, Brenchley PEC. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011; 7(10): 578-89.
Reichel H. Current treatment options in secondary renal hyperparathyroidism. Nephrol Dial Transplant 2006; 21(1): 23-8.
Sprague SM, Coyne D. Control of Secondary Hyperparathyroidism by Vitamin D Receptor Agonists in Chronic Kidney Disease. Clin J Am Soc Nephrol 2010; 5(3): 512-8.
Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73(12): 1345-54.